Citius Oncology, Inc. (CTOR)
NASDAQ: CTOR · Real-Time Price · USD
1.710
0.00 (0.00%)
Oct 13, 2025, 1:33 PM EDT - Market open
Citius Oncology Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Citius Oncology stock has a target of 6.00, which predicts a 250.88% increase from the current stock price of 1.71.
Price Target: $6.00 (+250.88%)
Analyst Consensus: Strong Buy
Analyst Ratings
According to 1 stock analyst, the rating for Citius Oncology is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
Total | 2 | 2 | 2 | 1 | 1 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $6 | Hold → Strong Buy | Upgrades | $6 | +250.88% | Sep 23, 2025 |
Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 23, 2025 |
Maxim Group | Maxim Group | Strong Buy Initiates $3 | Strong Buy | Initiates | $3 | +75.44% | Nov 27, 2024 |
EF Hutton | EF Hutton | Strong Buy Maintains $6 | Strong Buy | Maintains | $6 | +250.88% | Aug 13, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
63.72M
EPS This Year
-0.49
from -0.31
EPS Next Year
0.05
from -0.49
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 |
---|---|---|---|
High | n/a | 65.6M | |
Avg | n/a | 63.7M | |
Low | n/a | 61.2M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 |
---|---|---|---|
High | - | - | |
Avg | - | - | |
Low | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 |
---|---|---|---|
High | -0.50 | 0.05 | |
Avg | -0.49 | 0.05 | |
Low | -0.47 | 0.05 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 |
---|---|---|---|
High | - | - | |
Avg | - | - | |
Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.